A recent Finnish study has demonstrated that patients with rheumatic diseases can be safely and effectively switched from original-brand medicine to a biosimilar version.
A Reuters article reports that the results of the independent study were presented at the recent European League Against Rheumatism Congress in Rome, by one of its researchers, Tuulikki Sokka of Finland’s Jyvaskyla Central Hospital.
The study involved 39 patients with an average four years’ experience of Remicade, who were given the biosimilar Inflectra for 11 months. Patient symptoms and disease activity were found to be similar before and after the switch between the two treatments, and no immediate safety signals were observed.
